News

DermTech Publishes Clinical Data in the Journal of American Academy of Dermatology

For Immediate Release   DermTech Publishes Clinical Data in the Journal of American Academy of Dermatology   San Diego, July 14, 2014 (BUSINESS WIRE) – DermTech International (“DermTech”), a privately held molecular diagnostics company commercializing non-invasive gene expression tests for dermatology, announced the publication of a paper entitled, “Development of a novel

Read More »
Non Invasive Skin Biopsy Test

DermTech Selected as a Finalist for CONNECT’s 28th Annual Most Innovative New Product Awards Life Science Diagnostics & Research Tools

SAN DIEGO (SEPTEMBER 30, 2015) – Today, DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announced that its Pigmented Lesion Assay has been selected as a finalist in CONNECT’s Most Innovative New Product Awards. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great […]

Read More »

DermTech Granted Broad Patent for Skin Cancer Gene Classifier

San Diego, March 19, 2015  (BUSINESS WIRE) – DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announces that it has been issued a notice of allowance by the U.S. Patent Office for claims related to a gene classifier for pigmented skin lesion assessment. The gene classifier has been […]

Read More »

DermTech Presents Data at the American Academy of Dermatology Conference

San Diego, March 19, 2015 (BUSINESS WIRE) – DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announces the presentation of a poster at the 2015 American Academy of Dermatology’s Annual Meeting. The presentation entitled, “Melanoma gene expression in adhesive-tape sampled lesions is similar in primary tumors and patient […]

Read More »